PMID- 29080920
OWN - NLM
STAT- MEDLINE
DCOM- 20190304
LR  - 20200306
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Print)
IS  - 0941-4355 (Linking)
VI  - 26
IP  - 4
DP  - 2018 Apr
TI  - Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: 
      efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
PG  - 1151-1159
LID - 10.1007/s00520-017-3936-9 [doi]
AB  - PURPOSE: Patients receiving platinum-based chemotherapy are at high risk of 
      chemotherapy-induced nausea and vomiting (CINV), a distressing side effect of 
      treatment. This post-hoc subgroup analysis of two pivotal trials evaluated the 
      efficacy of NEPA in preventing CINV in subsets of patients with lung cancer who 
      received cisplatin or carboplatin. METHODS: In each study, the efficacy endpoints 
      complete response (CR; defined as no emetic episodes and no rescue medication) 
      and no significant nausea (NSN; defined as a score of < 25 mm on a visual analog 
      scale of 0-100 mm) during the acute (0-24 h), delayed (25-120 h), and overall 
      (0-120 h) phases post-chemotherapy in cycle 1 (study 1) and cycles 1-4 (study 2) 
      were assessed. Safety was evaluated by recording treatment-emergent adverse 
      events (AEs) and treatment-related AEs. RESULTS: NEPA treatment resulted in high 
      CR rates across the acute, delayed, and overall phases (cisplatin: > 88% overall 
      CR; carboplatin: > 75% overall CR), with higher CR rates for NEPA-treated 
      patients than those receiving palonosetron; moreover, CR rates were sustained 
      over multiple chemotherapy cycles (> 75%). High rates of NSN observed during 
      cycle 1 (> 79%) were also maintained over multiple chemotherapy cycles. NEPA was 
      well tolerated in all patients. CONCLUSIONS: NEPA appears to be effective and 
      well tolerated in patients with lung cancer receiving platinum-based 
      chemotherapy, across the acute, delayed, and overall phases and throughout 
      multiple cycles. As a highly effective oral combination antiemetic agent 
      administered as a single dose once per cycle, NEPA may offer a convenient, 
      simplified prophylactic antiemetic.
FAU - Hesketh, Paul J
AU  - Hesketh PJ
AD  - Lahey Health Cancer Institute, Lahey Hospital & Medical Center, 41 Mall Road, 
      Burlington, MA, 01805, USA. paul.hesketh@lahey.org.
FAU - Palmas, Marco
AU  - Palmas M
AD  - Corporate Clinical Development, Helsinn Healthcare SA, Lugano, Switzerland.
FAU - Nicolas, Pierre
AU  - Nicolas P
AD  - Helsinn Healthcare SA, Lugano, Switzerland.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20171028
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Antiemetics)
RN  - 0 (Pyridines)
RN  - 5D06587D6R (Palonosetron)
RN  - 7732P08TIR (netupitant)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiemetics/*therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nausea/chemically induced/*prevention & control
MH  - Palonosetron/pharmacology/*therapeutic use
MH  - Pyridines/pharmacology/*therapeutic use
MH  - Vomiting/chemically induced/*prevention & control
PMC - PMC5847067
OTO - NOTNLM
OT  - Carboplatin
OT  - Chemotherapy-induced nausea and vomiting (CINV)
OT  - Cisplatin
OT  - Lung cancer
OT  - NEPA
COIS- DATA: Authors have full control of all primary data and agree that the journal 
      may review the data if requested. CONFLICT OF INTEREST: PJH has no conflicts of 
      interest to declare. MP and PN are employees of Helsinn and may hold stock. 
      STATEMENT OF HUMAN RIGHTS: For this type of study, formal consent is not 
      required. STATEMENT ON THE WELFARE OF ANIMALS: This article does not contain any 
      studies with animals performed by any of the authors. STATEMENT ON INFORMED 
      CONSENT: Informed consent was obtained from all individual participants included 
      in the study.
EDAT- 2017/10/31 06:00
MHDA- 2019/03/05 06:00
PMCR- 2017/10/28
CRDT- 2017/10/30 06:00
PHST- 2017/03/29 00:00 [received]
PHST- 2017/10/16 00:00 [accepted]
PHST- 2017/10/31 06:00 [pubmed]
PHST- 2019/03/05 06:00 [medline]
PHST- 2017/10/30 06:00 [entrez]
PHST- 2017/10/28 00:00 [pmc-release]
AID - 10.1007/s00520-017-3936-9 [pii]
AID - 3936 [pii]
AID - 10.1007/s00520-017-3936-9 [doi]
PST - ppublish
SO  - Support Care Cancer. 2018 Apr;26(4):1151-1159. doi: 10.1007/s00520-017-3936-9. 
      Epub 2017 Oct 28.